Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids

American Journal of Transplantation

Volumn 8, Issue 5, 2008, Pages 984-989

  McDonald, R A ^a   Smith, J M ^a   Ho, M ^b   Lindblad, R ^b   Ikle, D ^c   Grimm, P ^d   Wyatt, R ^e,n   Arar, M ^f,q   Liereman, D ^g   Bridges, N ^h   Harmon, W ⁱ   Springate, J ^j   Warshaw, B ^k   El Dahr, S ^l   Bartosh, S ^m   Hurley, R ^o   Grimm, Paul ^p   Benfield, M ^r   McDonald, R ^s   Lum, G ^t   Weiss, R ^u   Kadry, Z ^v   Davis, I ^w   Fennel, R ^x   Munoz, R ^y   Mendley, S ^z   Wong, C ^aa   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b EMMES CORPORATION   (United States)

^c Pharmaceutical Product Development   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LE BONHEUR CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g BC CHILDREN S HOSPITAL   (Canada)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j CHILDREN S HOSPITAL OF BUFFALO   (United States)

^k Emory Children's Center   (United States)

^l TULANE UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF WISCONSIN   (United States)

ⁿ Children's Medical Center   (United States)

^o CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^p UCSD MEDICAL CENTER   (United States)

^q Christopher Goldsbury Center

^r UNIVERSITY OF ALABAMA   (United States)

^s SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^t CHILDREN S HOSPITAL   (United States)

^u WESTCHESTER MEDICAL CENTER   (United States)

^v PENN STATE COLLEGE OF MEDICINE   (United States)

^w CASE WESTERN RESERVE UNIVERSITY   (United States)

^x UNIVERSITY OF FLORIDA HEALTH   (United States)

^y HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^z UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^aa UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

EBV; Pediatric; PTLD; Renal transplant

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; HAZARD; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONITORING; MORBIDITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEWBORN; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VIRUS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TACROLIMUS;

EID: 42149091128     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02167.x     Document Type: Article

References (21)

1. Wehrenberg WB, Bergman PJ, Stagg L, Ndon J, Giustina A. Glucocorticoid inhibition of growth in rats: Partial reversal with somatostatin antibodies. Endocrinology 1990 127 : 2705 2708.
2. Robinson ICAF, Gabrielsson B, Klaus G, Mauras N, Holmberg C, Mehls O. Glucocorticoids and growth problems. Acta Paediatr 1995 S411 : 81 86.
3. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American pediatric renal transplant cooperative study (NAPRTCS). Transplantation 2001 71 : 1065 1068.
4. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996 10 : 248 255.
5. Ciancio G, Siquijor AP, Burke GW et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997 11 : 243 249.
6. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American pediatric renal transplant cooperative study. Pediatr Transplant 2002 6 : 396 399.
7. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: A report of the NAPRTCS. Am J Transplant 2004 4 : 384 389.
8. Cockfield SM, Preiksaitis JK, Jewell LD et al. Post-transplant lymphoproliferative disorder in renal allograft recipients: Clinical experience and risk factor analysis in a single center. Transplantation 1993 56 : 88 96.
9. Walker RC, Paya CV, Marshall WF et al. Pre-transplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplant lymphoproliferative disorder in adult heart, lung, and other solid organ transplantation. J Heart Lung Transplant 1995 12 : 214 221.
10. Ho M, Miller G, Atchison RW. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985 152 : 876 886.
11. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002 2 : 993 998.
12. Henle G, Henle W, Clifford P et al. Antibodies to Epstein-Barr virus in Burkitt;s lymphoma and control groups. J Natl Cancer Inst 1969 43 : 1147 1154.
13. Pereira MS, Blake JM, Macrae AD. EB virus antibody at different ages. Br Med J 1969 4 : 526 527.
14. Porter DD, Wimberly I, Benyesh-Melnick M. Prevalence of antibodies to EB virus and other herpesviruses. JAMA 1969 208 : 1675 1679.
15. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 1986 18 (2 Suppl 1 210 215.
16. Cherikh WS, Kaufmann M, Delmonico FL. A multivariate analysis of discharge immunosuppression and post-transplant malignancy. [abstract 868]. Am J Transplant 2001 1 : 353.
17. Ellis D, Jaffe R, Green M et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999 68 : 997 1003.
18. Kahan BD, Yakupoglu YK, Schoenberg L et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005 80 : 749 758.
19. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with TOR inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 889.
20. Kirk AD, Cherikh WS, Ring M et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007 7 : 2619 2625.
21. Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 : 262 274.